GENITOURINARY CANCERS

Neal D. Shore, MD, FACS, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Three presentations from the ASCO 2013 Annual Meeting extended positive findings comparing nab-paclitaxel and gemcitabine to gemcitabine in 861 untreated patients with advanced pancreatic cancer.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

The progression of prostate cancer to castration-resistant prostate cancer is a crucial change in the behavior of this cancer. Bony metastasis is a common finding that may cause symptoms such as pain.

In the wake of the approval of several novel treatments for prostate cancer, physicians must now focus on how best to integrate new therapies into the treatment of patients with prostate cancer.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of biomarkers in prostate cancer clinical trials.

The American Association for Cancer Research is an annual showcase of the latest scientific cancer research, with updates on phase I, often first-in-human clinical trials.

Although biomarkers have been shown to correlate with survival in prostate cancer, the use of biomarkers in the management of these patients may be dependent upon the clinical state and the class of drug evaluated.

Radium RA 223 dichloride has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.

Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.

Leonard G. Gomella, MD, from the Kimmel Cancer Center, discusses the utilization of circulating tumor cells in patients with solid tumors.

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.